Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study
Conclusion: A significant increase in hemorrhagic events by the use of dual or more AP agents and by co-administration of an AP agent and WF in patients on HD should be considered in planning their anti-thrombosis regimen.Kidney Blood Press Res 2017;42:553 –564
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Coumadin | Dialysis | Heart | Hemodialysis | Hemorrhagic Stroke | Ischemic Stroke | Kidney Transplant | Kidney Transplantation | Stroke | Study | Thrombosis | Transplants | Urology & Nephrology | Warfarin